The toxic effects of some relief of his symptoms. Aperients prescribed by his general practitioner had not relieved his constipation. His haemoglobin was 12-6 g/dl, mean corpuscular volume 81 fl, reticulocyte count 2-6% and a blood smear showed basophilic stippling. His blood lead concentration was raised at 5 .0,Lmol/l. His symptoms rapidly improved following intravenous chelation and he remains well with a blood lead of 288pmol/l. Case 4 A 26 year old labourer had been working with the three men described above for the previous five weeks. He was asymptomatic. His haemoglobin concentration was 15 2 g/dl, mean corpuscular volume 93 fl, reticulocyte count 2-000with an occasional stippled red cell.
Blood lead concentration was 3-1 JLmol/l. He did not reattend after his first visit so further investigations were not possible.
Methods
Blood lead concentrations were estimated on venous blood anticoagulated with K3EDTA, in a vacutainer. The blood was diluted and the lead measured using graphite furnace atomic absorption spectrophotometry (GFAAS) on a Perkin Elmer 5000, with an HGA 400 furnace. Additional dilution was necessary for samples from cases 1 and 2 which were much higher than usual industrial samples-that is, below 4 0 jmol/l.
Urine lead excretion was measured at the New Cross Supraregional Assay Service (SAS) trace element laboratory using GFAAS. Urinary aminolaevulinic acid and porphobilinogen were measured by standard methods." Uroporphyrin I + III and total coproporphyrin I + III were measured by specific high performance liquid chromatographic techniques."2 Erythrocyte zinc protoporphyrin (ZPP) was measured by standard techniques. '3 Erythrocyte aminolaevulinic acid (ALA) dehydratase with and without dithiothreitol was measured using high performance liquid chromatography to determine porphobilinogen formation. '4 The physiological effects on renal glomerular function were assessed by measuring creatinine clearance, urinary amino acids, phosphate and glucose. Arsenic, antimony and cobalt were also measured. Pyrimidine-5'-nucleotidase (Pyr-5'-N) activity was measured by a modified'5 non-isotopic method. ' In Britain the performance of blood lead analysis has improved dramatically since the seventies and the test is widely available through the SAS and other laboratories. This has been due to: (i) the advent of GFAAS; (2) the establishment of quality assessment schemes (SAS Trace Element Reference Laboratory, University of Surrey and the United Kingdom National External Quality Assessment Scheme); and (iii) the characterisation of stable reference materials, which have enabled the SAS laboratories to achieve coefficients of variation less than 60o 24 The definitive test for assessing the body burden of lead is the urinary excretion of lead following a challenge with calcium EDTA. Blood lead concentrations have shown the best correlation with this, provided that the lead exposure is current.25 Erythrocyte protoporphyrin or ZPP depends on the lead present as the erythrocyte was formed, so the blood concentrations reflect the exposure over a longer period than blood lead. Although raised in our cases, it is not reliable for diagnosing or monitoring mild degrees of exposure, but its simplicity had led to wide application in screening programmes. Similarly, urinary lead, ALA, and coproporphyrins are either too insensitive or too variable for this purpose with sample volume and renal function being further additional limitations.26 Direct measurement of ALA dehydratase activity has been used, but the estimation is very sensitive to even small excesses of lead and furthermore, alcohol affects the enzyme activity.27 For these reasons it is little used as a marker of lead exposure. Lead also inhibits ferrochelatase (haem synthetase) which catalyses the introduction of ferrous iron into the porphyrin ring to form haem. This test, however, is limited in its availability and reproducibility. In general, analysis of blood lead remains the single most useful index of recent exposure with the other estimations providing supportive evidence. 28 Anaemia, reticulocytosis, and basophilic stippling have been recognised in lead poisoning since the start of the century. Lead binds avidly to the red cells9 with up to 50 times as much being found in the bone marrow.8 The abnormalities are confined to the erythroid series, with ineffective erythroid hyperplasia being prominent. Ring sideroblasts are commonly reported8 but these were absent in our patient (case 1) despite dyserythropoietic changes (fig 3) . The formation of ringed sideroblasts has been attributed to a decreased activity of the haem synthetic enzymes, particularly ALA synthetase, leading to intramitochondrial iron accumulation. 29 albeit producing only about a 40°h reduction in Pyr-5'-N activity, has been reported to have no effect on the maximum activities of the glycolytic enzymes, as measured in vitro.32 The effect of acute lead intoxication on glycolytic intermediates needs further assessment.
The treatment of lead poisoning is initiated by prompt removal from exposure. Chelation treatment, which can be given both orally and intravenously, should be considered when the symptoms are severe or when the lead concentration is dangerously high (> 5 0 yimol/l). In severe poisoning sodium calcium EDTA is most effective but a rebound phenomenon may occur when the agent is stopped. New water soluble derivatives of BAL called dimercaptosuccinic acid (DMSA) and 2,3 dimercaptopropene-1 -sulphonate (DMPS) have been shown to be effective. Skin rashes (case 1) are recognised with DMPS,'5 although erythema multiforme has not previously been reported.
The acute clinical, biochemical, and haematological features of lead toxicity are well documented, yet the long term sequelae remain uncertain and despite large cohort studies no reproducible abnormality has been reported in adults.3334 With demolition and reconstruction work again becoming prevalent in many inner cities de novo lead poisoning should be considered if there are clinical pointers. This initial suspicion can easily be confirmed with reproducible biochemical and haematological investigations.
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